Histone deacetylase inhibitor trichostatin A (TSA) rescues mozmutant homeosis and hox gene expression defects
| . | Genotype and treatment . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Treatment . | b719+/b719+ +DMSO . | b719−/b719− +DMSO . | b719+/b719+ +TSA . | b719−/b719− +TSA . | |||
| n | 31 | 26 | 24 | 39 | |||
| % with phenotype (n) | |||||||
| Dorsal deletion | 0 (0.0) | 69 (18.0) | 0 (0.0) | 22 (8.5) | |||
| Dorsal shape change | 0 (0.0) | 100 (26.0) | 46 (11.0) | 76 (29.5) | |||
| Ventral inversion | 0 (0.0) | 95 (25.0) | 0 (0.0) | 8 (3.0) | |||
| Ventral shape change | 0 (0.0) | 52 (13.5) | 0 (0.0) | 6 (2.5) | |||
| Ventral fusion | 0 (0.0) | 60 (15.5) | 0 (0.0) | 0 (0.0) | |||
| Dorsal fusion | 0 (0.0) | 39 (10.0) | 0 (0.0) | 0 (0.0) | |||
| . | Genotype and treatment . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Treatment . | b719+/b719+ +DMSO . | b719−/b719− +DMSO . | b719+/b719+ +TSA . | b719−/b719− +TSA . | |||
| n | 31 | 26 | 24 | 39 | |||
| % with phenotype (n) | |||||||
| Dorsal deletion | 0 (0.0) | 69 (18.0) | 0 (0.0) | 22 (8.5) | |||
| Dorsal shape change | 0 (0.0) | 100 (26.0) | 46 (11.0) | 76 (29.5) | |||
| Ventral inversion | 0 (0.0) | 95 (25.0) | 0 (0.0) | 8 (3.0) | |||
| Ventral shape change | 0 (0.0) | 52 (13.5) | 0 (0.0) | 6 (2.5) | |||
| Ventral fusion | 0 (0.0) | 60 (15.5) | 0 (0.0) | 0 (0.0) | |||
| Dorsal fusion | 0 (0.0) | 39 (10.0) | 0 (0.0) | 0 (0.0) | |||
All animals were PCR-genotyped. See Table 2 legend for scoring method and explanation of phenotypes and abbreviations. The HS disorganization in TSA-treated embryos, while disorganized relative to the untreated wild-type pattern, lacked shape changes characteristic of moz mutants.